Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°íȯÁ¾¾çÀÇ Ä¡·á¼ºÀû ¹× Á¾¾ç MarkerÀÇ ÀÓ»óÀû °íÂû Treatment of Testicular Tumor & Clinical Evaluation of Tumor Marker

´ëÇѺñ´¢±â°úÇÐȸÁö 1986³â 27±Ç 1È£ p.103 ~ 110
¼Ò¼Ó »ó¼¼Á¤º¸
±ÇÇ念/Kwon HY À±ÁøÇÑ/Yoon JH

Abstract


Treatment and clinical evaluation of tumor marker were made on 24 patients with testicular tumors, which were admitted to the Pusan National University Hospital From Jan. l970 to Dec. l984.
There were 6 cases of infantile type embryonal carcinoma and 6 cases of teratoma in children.

In adult, there were 5 cases of seminoma, 2 cases of embryonal carcinoma, 2 cases of teratoma, 1 case of choriocarcinoma, 1 case of yolk sac tumor and l case of seminoma with embryonal carcinoma.

Over 2 years follow-up study was made on 19 cases.

The results are summarized as follows:

l. 2-year survival rate was 6l.1%.

2. After initiation of PVB chemotherapy for advanced testicular tumor since l982, survival rate was improved.

3. The rates of elevated AFP were high in advanced nonseminomatous testicular tumor, therefore the survival rates were poorer in patients with elevation of serum AFP. But the difference of the survival rates between AFP positive and negative patients diminished during the latest 3 years.

Å°¿öµå

°íȯÁ¾¾ç; Á¾¾çÇ¥Áö; tumor marker; testicular tumor

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS